VaziriKSchwartzSGKishorKFlynnHWJr. Endophthalmitis: state of the art. Clin Ophthalmol. 2015;9:95–108. doi:10.2147/OPTH.S76406
2.
YannuzziNAGregoriNZRosenfeldPJ. Endophthalmitis associated with intravitreal injections of anti-VEGF agents at a tertiary referral center: in-house and referred cases. Ophthalmic Surg Lasers Imaging Retina. 2018;49(5):313–319. doi:10.3928/23258160-20180501-04
3.
BakriSJLarsonTAEdwardsAO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246(5):779–781. doi:10.1007/s00417-007-0754-7
4.
KayCNTarantolaRMGehrsKM. Uveitis following intravitreal bevacizumab: a non-infectious cluster. Ophthalmic Surg Lasers Imaging. 2011;42(4):292–296. doi:10.3928/15428877-20110603-04
5.
KhananiAMCohenGLZawadzkiR. A prospective masked clinical assessment of inflammation after intravitreal injection of ranibizumab or aflibercept. J Ocul Pharmacol Ther. 2016;32(4):216–218. doi:10.1089/jop.2015.0152
GoldbergRAShahCPWiegandTWHeierJS. Noninfectious endophthalmitis after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol. 2014;158(4):733–737. doi:10.1016/j.ajo.2014.06.019
RothDBFlynnHWJr. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol. 2008;146(3):346–347. doi:10.1016/j.ajo.2008.04.037
